Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.’s antibody-drug conjugate (ADC) ifinatamab deruxtecan produced a confirmed 48.2% objective response rate in a phase II study of previously treated patients with extensive-stage small-cell lung cancer.
Positive phase I results in small-cell lung cancer (SCLC) from Ideaya Biosciences Inc. and partner Hengrui Pharmaceuticals Co. Ltd. with IDE-849, a potentially first-in-class antibody-drug conjugate targeting delta-like ligand 3 (DLL3) and topoisomerase 1, sharpened interest in the DLL3 mechanism, which gave Zai Lab Ltd. a phase Ia/Ib win this year in extensive-stage (ES) SCLC.
Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.’s antibody-drug conjugate (ADC) ifinatamab deruxtecan produced a confirmed 48.2% objective response rate in a phase II study of previously treated patients with extensive-stage small-cell lung cancer.
Results from the global phase III Harmoni trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) showed a statistically significant increase in progression-free survival after treatment with ivonescimab plus chemotherapy compared to chemotherapy alone, but failed to show a statistically significant benefit in overall survival (OS).
More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) in PD-L1-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer over the weekend, Summit rolled out detailed data from the phase III Harmoni-2 trial, which included a nearly doubling of progression-free survival for ivonescimab compared to Merck & Co. Inc.’s established blockbuster drug.
More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) in PD-L1-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer over the weekend, Summit rolled out detailed data from the phase III Harmoni-2 trial, which included a nearly doubling of progression-free survival for ivonescimab compared to Merck & Co. Inc.’s established blockbuster drug.
Driven by advances in scientific understanding, the treatment of non-small-cell lung cancer (NSCLC) has begun to see successes one subtype at a time. At the 2021 World Conference on Lung Cancer (WCLC), which is currently being held in virtual format, researchers were optimistic that the same path would be possible for small-cell lung cancer (SCLC).
Driven by advances in scientific understanding, the treatment of non-small cell lung cancer (NSCLC) has begun to see successes one subtype at a time. At the 2021 World Conference on Lung Cancer (WCLC), which is currently being held in virtual format, researchers were optimistic that the same path would be possible for small-cell lung cancer (SCLC).
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
